WO2008035377A3 - Novel intermediates for the preparation of camptothecin analogues - Google Patents
Novel intermediates for the preparation of camptothecin analogues Download PDFInfo
- Publication number
- WO2008035377A3 WO2008035377A3 PCT/IN2007/000381 IN2007000381W WO2008035377A3 WO 2008035377 A3 WO2008035377 A3 WO 2008035377A3 IN 2007000381 W IN2007000381 W IN 2007000381W WO 2008035377 A3 WO2008035377 A3 WO 2008035377A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preparation
- salts
- camptothecin analogues
- novel intermediates
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The present invention relates to novel intermediate compounds of formula (Ia) and its salts thereof, wherein R is an amino protecting group, R1 is selected from the group consisting of hydrogen, an alkyl, araalkyl, hydroxymethyl, carboxymethyl, acyloxymethyl, trialkylsilyl or an N-substituted alkyl amine where nitrogen forms the linking atom. The invention also relates to the use of these novel intermediate compounds of formula (Ia) for the preparation of camptothecin analogues and its salts, more particularly the anti-cancer drug irinotecan and its pharmaceutically accepted salts.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1704/CHE/2006 | 2006-09-18 | ||
IN1704CH2006 | 2006-09-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008035377A2 WO2008035377A2 (en) | 2008-03-27 |
WO2008035377A3 true WO2008035377A3 (en) | 2009-01-08 |
Family
ID=39200977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2007/000381 WO2008035377A2 (en) | 2006-09-18 | 2007-08-31 | Novel intermediates for the preparation of camptothecin analogues |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008035377A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8546573B2 (en) * | 2009-11-18 | 2013-10-01 | Cadila Healthcare Limited | Process for the preparation of 7-ethyl-10-[4-(1-piperidino)-1-piperdino] carbonyloxy-camptothecin hydrochloride trihydrate |
CN102643283A (en) * | 2012-05-08 | 2012-08-22 | 江苏红豆杉生物科技有限公司 | Method for preparing irinotecan hydrochloride trihydrate pure product |
US8722886B1 (en) * | 2012-11-13 | 2014-05-13 | Bionumerik Pharmaceuticals, Inc. | Methods for the total chemical synthesis of enantiomerically-pure 7-(2′-trimethylsilyl)ethyl camptothecin |
EP2881396A1 (en) * | 2013-12-03 | 2015-06-10 | Synbias Pharma AG | Method for the synthesis of irinotecan |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003089413A1 (en) * | 2002-04-17 | 2003-10-30 | Pharmacia Corporation | Pharmacia corporation |
US20040235878A1 (en) * | 2003-05-12 | 2004-11-25 | Scinopharm Taiwan, Ltd. | Process for the preparation of 7-alkyl-10-hydroxy-20(S)-camptothecin |
US20050208146A1 (en) * | 2003-10-30 | 2005-09-22 | Pfizer Inc | Novel dosage and administration method for oral camptosar |
-
2007
- 2007-08-31 WO PCT/IN2007/000381 patent/WO2008035377A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003089413A1 (en) * | 2002-04-17 | 2003-10-30 | Pharmacia Corporation | Pharmacia corporation |
US20040235878A1 (en) * | 2003-05-12 | 2004-11-25 | Scinopharm Taiwan, Ltd. | Process for the preparation of 7-alkyl-10-hydroxy-20(S)-camptothecin |
US20050208146A1 (en) * | 2003-10-30 | 2005-09-22 | Pfizer Inc | Novel dosage and administration method for oral camptosar |
Also Published As
Publication number | Publication date |
---|---|
WO2008035377A2 (en) | 2008-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008012635A3 (en) | Amine derivatives useful as anticancer agents | |
MX2011012627A (en) | Substituted aminobutyric derivatives as neprilysin inhibitors. | |
MY140528A (en) | Spiroketal derivatives and their use as therapeutic agents for diabetes | |
WO2007095174A3 (en) | Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions | |
MY145031A (en) | N-(aminoheteroaryl)-1h-indole-2carboxamide derivatives, and preparation and therapeutic application thereof | |
TW200642683A (en) | Heterocyclic compound | |
MX2008014908A (en) | Novel heterocyclic compound or salt thereof and intermediate thereof. | |
SI2091948T1 (en) | Novel inhibitors of glutaminyl cyclase | |
WO2008097459A3 (en) | Dual-acting antihypertensive agents | |
WO2007084914A3 (en) | Phenoxy-substituted pyrimidines as adenosine receptor antagonists | |
MX2009011487A (en) | Dual-acting antihypertensive agents. | |
WO2009155121A3 (en) | Inhibitors of pi3 kinase | |
WO2008108380A3 (en) | Pyrrole compounds | |
MX344669B (en) | Novel anti-platelet agent. | |
WO2008108378A3 (en) | Bicyclic oxomorpholine derivative | |
TW200728307A (en) | Novel spirochromanone derivatives | |
WO2007138472A3 (en) | Triazolopyridazine derivatives | |
TW200833675A (en) | Nicotinamide derivatives | |
WO2010011821A3 (en) | Dual-acting antihypertensive agents | |
HK1138262A1 (en) | Novel phosphodiesterase inhibitors | |
MY145066A (en) | Methods for treating sexual dysfunction | |
MX2009003927A (en) | Thioglucose spiroketal derivative and use thereof as therapeutic agent for diabetes. | |
WO2007109578A3 (en) | Substituted gamma lactams as prostaglandin ep2 agonists | |
JO3067B1 (en) | Pyrazolylaminopyridines as inhibitors of fak | |
WO2008003854A3 (en) | Derivatives of 2-benzoyl-imidazopyridines, preparation method thereof and use of same in therapeutics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07827552 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07827552 Country of ref document: EP Kind code of ref document: A2 |